시장보고서
상품코드
1193092

치매 치료제 시장 : 적응증별, 약물 클래스별, 유통 채널별 - 세계 기회 분석 및 산업 예측(2021-2031년)

Dementia Drugs Market By Indication, By Drug Class, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2031

발행일: | 리서치사: Allied Market Research | 페이지 정보: 영문 265 Pages | 배송안내 : 2-3일 (영업일 기준)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

치매 치료제의 세계 시장은 2021년에 86억 6,217만 달러를 기록하고, 2022년부터 2031년에 걸쳐 CAGR 8.5%를 기록하며, 2031년에는 197억 427만 달러에 달할 것으로 예측됩니다. .

치매는 사고, 행동, 기억, 일상생활 동작의 능력에 열화가 보이는 증후군입니다. 가장 흔한 치매의 형태는 알츠하이머 병입니다. 치매는 주로 또는 이차적으로 뇌에 영향을 미치는 많은 상해와 질병에 의해 유발됩니다. 치매에 대한 인식이 낮고, 그 결과, 검사나 개호에 지장을 초래하고 있는 경우가 많습니다. 콜린에스테라아제 억제제는 가장 일반적으로 처방되는 약제로 학습이나 기억, 기분전환에 필수적인 아세틸콜린의 뇌내 분해를 억제하는 작용이 있습니다.

치매 치료제 시장은 알츠하이머병의 유병률 증가, 의약품 개발을 위한 연구개발 활동의 진전, 조기진단의 보급 등에 의해 예측기간 중에 크게 성장할 것으로 보입니다. 또한 노인 인구 증가, 연구개발 투자 증가, 강력한 파이프라인 후보의 존재, 의료 인프라 정비를 위한 지출 증가, 개발도상지역의 질병 예방에 관한 국민의식 증가, 개별 화의료에 대한 수요의 증가 등이 시장의 성장을 더욱 촉진하고 있습니다. 그러나 제품 승인과 관련된 정부의 엄격한 규제 및 R&D 활동과 관련된 높은 비용이 시장 성장을 방해할 것으로 예상됩니다. 한편 창약기술의 기술 진보 가속화와 정부의 의약품 개발에 대한 높은 투자는 업계에 새로운 길을 여는 요인으로 치매 치료제 시장에 큰 성장 기회를 가져올 것으로 예상됩니다.

치매 치료제 시장은 적응증, 약물 클래스, 유통 채널, 지역에 따라 구분됩니다. 적응증별로는, 레비 소체형 치매, 파킨슨 병형 치매, 알츠하이머병, 혈관성 치매, 그 외의 적응증으로 이분되고, 약물 클래스별로는, 레비 소체형 치매, 파킨슨 병형 치매, 알츠하이머 병형 치매, 혈관성 치매 및 기타 적응증으로 이분됩니다. 마약 등급에 따라 시장은 콜린 에스테라아제 억제제와 NMDA 길항제 및 그 병용 약물로 분류됩니다. 유통 경로별로는 병원 약국, 소매 약국, 온라인 약국으로 분류됩니다.

목차

제1장 소개

제2장 주요 요약

제3장 시장 개요

  • 시장의 정의와 범위
  • 주요 조사 결과
    • 주요 투자 포켓
  • Porter's Five Forces 분석
  • 주요 기업의 포지셔닝
  • 시장 역학
    • 촉진 요인
    • 억제 요인
    • 기회
  • COVID-19 영향 분석

제4장 치매 치료제 시장 : 적응증별

  • 개요
    • 시장 규모 및 예측
  • 레비 소체형 치매
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모·예측 : 지역별
    • 시장 점유율 분석 : 국가별
  • 파킨슨스 병형 치매
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모·예측 : 지역별
    • 시장 점유율 분석 : 국가별
  • 알츠하이머형 치매
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모·예측 : 지역별
    • 시장 점유율 분석 : 국가별
  • 혈관성 치매
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모·예측 : 지역별
    • 시장 점유율 분석 : 국가별
  • 기타 적응증
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모·예측 : 지역별
    • 시장 점유율 분석 : 국가별

제5장 치매 치료제 시장 : 약효 분류별

  • 개요
    • 시장 규모 및 예측
  • 콜린에스테라아제 억제제
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모 및 예측 : 지역별
    • 시장 점유율 분석 : 국가별
  • NMDA 길항제와 그 병용약
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모·예측 : 지역별
    • 시장 점유율 분석 : 국가별

제6장 치매 치료제 시장 : 유통 채널별

  • 개요
    • 시장 규모·예측
  • 소매 약국
    • 주요 시장 동향, 성장 요인과 기회
    • 시장 규모·예측 : 지역별
    • 시장 점유율 분석 : 국가별
  • 병원 약국
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모·예측 : 지역별
    • 시장 점유율 분석 : 국가별
  • 온라인 약국
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모·예측 : 지역별
    • 시장 점유율 분석 : 국가별

제7장 치매 치료제 시장 : 지역별

  • 개요
    • 시장 규모·예측
  • 북미
    • 주요 동향과 기회
    • 북미 시장 규모·예측 : 적응증별
    • 북미 시장 규모·예측 : 약물 클래스별
    • 북미 시장 규모·예측 : 유통 채널별
    • 북미 시장 규모·예측 : 국가별
      • 미국
      • 캐나다
      • 멕시코
  • 유럽
    • 주요 동향과 기회
    • 유럽의 시장 규모·예측 : 적응증별
    • 유럽 시장 규모·예측 : 약물 클래스별
    • 유럽 시장 규모·예측 : 유통 채널별
    • 유럽 시장 규모·예측 : 국가별
      • 독일
      • 프랑스
      • 영국
      • 이탈리아
      • 스페인
      • 기타 유럽
  • 아시아태평양
    • 주요 동향과 기회
    • 아시아태평양의 시장 규모·예측 : 적응증별
    • 아시아태평양의 시장 규모·예측 : 약물 클래스별
    • 아시아태평양의 시장 규모·예측 : 유통 채널별
    • 아시아태평양의 시장 규모·예측 : 국가별
      • 중국
      • 일본
      • 인도
      • 한국
      • 호주
      • 기타 아시아태평양
  • LAMEA
    • 주요 동향과 기회
    • LAMEA의 시장 규모·예측 : 적응증별
    • LAMEA의 시장 규모·예측 : 약물 클래스별
    • LAMEA의 시장 규모·예측 : 유통채널별
    • LAMEA의 시장 규모·예측 : 국가별
      • 브라질
      • 사우디아라비아
      • 남아프리카 공화국
      • 기타 LAMEA

제8장 기업 정세

  • 소개
  • 주요 성공 전략
  • 주요 10개사의 제품 매핑
  • 경쟁 대시보드
  • 경합의 히트 맵
  • 주요 발전

제9장 기업 프로필

  • apotex inc.
  • Aurobindo Pharma Ltd
  • Biogen Idec
  • Eisai
  • Eli Lilly and Company
  • Johnson & Johnson
  • Abbvie Inc
  • F. Hoffmann-La Roche AG
  • Teva Pharmaceutical Industries
  • Novartis AG
ksm 23.03.27

The global dementia drugs market accounted for $8662.17 million in 2021, and is expected to reach $19704.27 million by 2031, registering a CAGR of 8.5% from 2022 to 2031.

Dementia is a syndrome in which there is deterioration in thinking, behavior, memory, and ability to perform daily activities. The most common form of dementia is Alzheimer disease. Dementia results from many injuries and disease that primarily or secondarily impact the brain. There is often lack of awareness about dementia, which results in obstacles to examination and care. Cholinesterase Inhibitors are most commonly prescribed medicines, which help prevent break down of acetylcholine in the brain as acetylcholine is essential in learning, memory, and mood of individual.

It is estimated that the dementia drugs market is expected to experience significant market growth during the forecast period owing to increase in the prevalence of Alzheimer's disease, advancement in R&D activities for drug development, and rise in adoption of early diagnosis. In addition, the growing geriatric population, increase in investment by players in R&D and presence of robust pipeline candidates, rise in expenditure on the development of healthcare infrastructure, increase in public awareness about the disease prevention in developing regions, and surge in demand for personalized medicine, further facilitate the growth of the market. However, strict government regulation related to product approval and high cost linked to R&D activity are expected to impede the market growth. In contrast, accelerated technological advancement in drug discovery technique and high investment by the government for drug development are factors that present new pathway in the industry, which are anticipated to provide significant growth opportunities for the dementia drugs market.

The dementia drugs market is segmented on the basis of indication, drug class, distribution channel, and region. On the basis of indication, the market is bifurcated into Lewy body dementia, Parkinson's disease dementia, Alzheimer's disease, vascular dementia, and other indications. Depending on drug class, the market is classified into cholinesterase inhibitors and NMDA antagonist and its combination drugs. By distribution channel, the market is classified into hospital pharmacy, retail pharmacy, and online pharmacy.

Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

The report provides a comprehensive analysis of the key players that operate in the global dementia dugs market. The key companies profiled in the report include AbbVie Inc., APPOTEX Inc., Aurobindo Pharma Limited, Biogen Idec Inc., EISAI GLOBAL, Eli Lilly and company, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Novartis AG and Teva Pharmaceuticals

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the dementia drugs market analysis from 2021 to 2031 to identify the prevailing dementia drugs market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the dementia drugs market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global dementia drugs market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Indication

  • Lewy Body Dementia
  • Parkinsons Disease Dementia
  • Alzheimers Disease
  • Vascular Dementia
  • Other Indications

By Drug Class

  • Cholinesterase Inhibitors
  • NMDA Antagonists and its Combination Drugs

By Distribution Channel

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
  • Key Market Players
    • apotex inc.
    • Aurobindo Pharma Ltd
    • Biogen Idec
    • Eisai
    • Eli Lilly and Company
    • Johnson & Johnson
    • Abbvie Inc
    • , F. Hoffmann-La Roche AG
    • Teva Pharmaceutical Industries
    • Novartis AG

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: DEMENTIA DRUGS MARKET, BY INDICATION

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Lewy Body Dementia
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market share analysis by country
  • 4.3 Parkinsons Disease Dementia
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market share analysis by country
  • 4.4 Alzheimers Disease
    • 4.4.1 Key market trends, growth factors and opportunities
    • 4.4.2 Market size and forecast, by region
    • 4.4.3 Market share analysis by country
  • 4.5 Vascular Dementia
    • 4.5.1 Key market trends, growth factors and opportunities
    • 4.5.2 Market size and forecast, by region
    • 4.5.3 Market share analysis by country
  • 4.6 Other Indications
    • 4.6.1 Key market trends, growth factors and opportunities
    • 4.6.2 Market size and forecast, by region
    • 4.6.3 Market share analysis by country

CHAPTER 5: DEMENTIA DRUGS MARKET, BY DRUG CLASS

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 Cholinesterase Inhibitors
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market share analysis by country
  • 5.3 NMDA Antagonists and its Combination Drugs
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market share analysis by country

CHAPTER 6: DEMENTIA DRUGS MARKET, BY DISTRIBUTION CHANNEL

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 Retail Pharmacies
    • 6.2.1 Key market trends, growth factors and opportunities
    • 6.2.2 Market size and forecast, by region
    • 6.2.3 Market share analysis by country
  • 6.3 Hospital Pharmacies
    • 6.3.1 Key market trends, growth factors and opportunities
    • 6.3.2 Market size and forecast, by region
    • 6.3.3 Market share analysis by country
  • 6.4 Online Pharmacies
    • 6.4.1 Key market trends, growth factors and opportunities
    • 6.4.2 Market size and forecast, by region
    • 6.4.3 Market share analysis by country

CHAPTER 7: DEMENTIA DRUGS MARKET, BY REGION

  • 7.1 Overview
    • 7.1.1 Market size and forecast
  • 7.2 North America
    • 7.2.1 Key trends and opportunities
    • 7.2.2 North America Market size and forecast, by Indication
    • 7.2.3 North America Market size and forecast, by Drug Class
    • 7.2.4 North America Market size and forecast, by Distribution Channel
    • 7.2.5 North America Market size and forecast, by country
      • 7.2.5.1 U.S.
      • 7.2.5.1.1 Key market trends, growth factors and opportunities
      • 7.2.5.1.2 Market size and forecast, by Indication
      • 7.2.5.1.3 Market size and forecast, by Drug Class
      • 7.2.5.1.4 Market size and forecast, by Distribution Channel
      • 7.2.5.2 Canada
      • 7.2.5.2.1 Key market trends, growth factors and opportunities
      • 7.2.5.2.2 Market size and forecast, by Indication
      • 7.2.5.2.3 Market size and forecast, by Drug Class
      • 7.2.5.2.4 Market size and forecast, by Distribution Channel
      • 7.2.5.3 Mexico
      • 7.2.5.3.1 Key market trends, growth factors and opportunities
      • 7.2.5.3.2 Market size and forecast, by Indication
      • 7.2.5.3.3 Market size and forecast, by Drug Class
      • 7.2.5.3.4 Market size and forecast, by Distribution Channel
  • 7.3 Europe
    • 7.3.1 Key trends and opportunities
    • 7.3.2 Europe Market size and forecast, by Indication
    • 7.3.3 Europe Market size and forecast, by Drug Class
    • 7.3.4 Europe Market size and forecast, by Distribution Channel
    • 7.3.5 Europe Market size and forecast, by country
      • 7.3.5.1 Germany
      • 7.3.5.1.1 Key market trends, growth factors and opportunities
      • 7.3.5.1.2 Market size and forecast, by Indication
      • 7.3.5.1.3 Market size and forecast, by Drug Class
      • 7.3.5.1.4 Market size and forecast, by Distribution Channel
      • 7.3.5.2 France
      • 7.3.5.2.1 Key market trends, growth factors and opportunities
      • 7.3.5.2.2 Market size and forecast, by Indication
      • 7.3.5.2.3 Market size and forecast, by Drug Class
      • 7.3.5.2.4 Market size and forecast, by Distribution Channel
      • 7.3.5.3 UK
      • 7.3.5.3.1 Key market trends, growth factors and opportunities
      • 7.3.5.3.2 Market size and forecast, by Indication
      • 7.3.5.3.3 Market size and forecast, by Drug Class
      • 7.3.5.3.4 Market size and forecast, by Distribution Channel
      • 7.3.5.4 Italy
      • 7.3.5.4.1 Key market trends, growth factors and opportunities
      • 7.3.5.4.2 Market size and forecast, by Indication
      • 7.3.5.4.3 Market size and forecast, by Drug Class
      • 7.3.5.4.4 Market size and forecast, by Distribution Channel
      • 7.3.5.5 Spain
      • 7.3.5.5.1 Key market trends, growth factors and opportunities
      • 7.3.5.5.2 Market size and forecast, by Indication
      • 7.3.5.5.3 Market size and forecast, by Drug Class
      • 7.3.5.5.4 Market size and forecast, by Distribution Channel
      • 7.3.5.6 Rest of Europe
      • 7.3.5.6.1 Key market trends, growth factors and opportunities
      • 7.3.5.6.2 Market size and forecast, by Indication
      • 7.3.5.6.3 Market size and forecast, by Drug Class
      • 7.3.5.6.4 Market size and forecast, by Distribution Channel
  • 7.4 Asia-Pacific
    • 7.4.1 Key trends and opportunities
    • 7.4.2 Asia-Pacific Market size and forecast, by Indication
    • 7.4.3 Asia-Pacific Market size and forecast, by Drug Class
    • 7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
    • 7.4.5 Asia-Pacific Market size and forecast, by country
      • 7.4.5.1 China
      • 7.4.5.1.1 Key market trends, growth factors and opportunities
      • 7.4.5.1.2 Market size and forecast, by Indication
      • 7.4.5.1.3 Market size and forecast, by Drug Class
      • 7.4.5.1.4 Market size and forecast, by Distribution Channel
      • 7.4.5.2 Japan
      • 7.4.5.2.1 Key market trends, growth factors and opportunities
      • 7.4.5.2.2 Market size and forecast, by Indication
      • 7.4.5.2.3 Market size and forecast, by Drug Class
      • 7.4.5.2.4 Market size and forecast, by Distribution Channel
      • 7.4.5.3 India
      • 7.4.5.3.1 Key market trends, growth factors and opportunities
      • 7.4.5.3.2 Market size and forecast, by Indication
      • 7.4.5.3.3 Market size and forecast, by Drug Class
      • 7.4.5.3.4 Market size and forecast, by Distribution Channel
      • 7.4.5.4 South Korea
      • 7.4.5.4.1 Key market trends, growth factors and opportunities
      • 7.4.5.4.2 Market size and forecast, by Indication
      • 7.4.5.4.3 Market size and forecast, by Drug Class
      • 7.4.5.4.4 Market size and forecast, by Distribution Channel
      • 7.4.5.5 Australia
      • 7.4.5.5.1 Key market trends, growth factors and opportunities
      • 7.4.5.5.2 Market size and forecast, by Indication
      • 7.4.5.5.3 Market size and forecast, by Drug Class
      • 7.4.5.5.4 Market size and forecast, by Distribution Channel
      • 7.4.5.6 Rest of Asia-Pacific
      • 7.4.5.6.1 Key market trends, growth factors and opportunities
      • 7.4.5.6.2 Market size and forecast, by Indication
      • 7.4.5.6.3 Market size and forecast, by Drug Class
      • 7.4.5.6.4 Market size and forecast, by Distribution Channel
  • 7.5 LAMEA
    • 7.5.1 Key trends and opportunities
    • 7.5.2 LAMEA Market size and forecast, by Indication
    • 7.5.3 LAMEA Market size and forecast, by Drug Class
    • 7.5.4 LAMEA Market size and forecast, by Distribution Channel
    • 7.5.5 LAMEA Market size and forecast, by country
      • 7.5.5.1 Brazil
      • 7.5.5.1.1 Key market trends, growth factors and opportunities
      • 7.5.5.1.2 Market size and forecast, by Indication
      • 7.5.5.1.3 Market size and forecast, by Drug Class
      • 7.5.5.1.4 Market size and forecast, by Distribution Channel
      • 7.5.5.2 Saudi Arabia
      • 7.5.5.2.1 Key market trends, growth factors and opportunities
      • 7.5.5.2.2 Market size and forecast, by Indication
      • 7.5.5.2.3 Market size and forecast, by Drug Class
      • 7.5.5.2.4 Market size and forecast, by Distribution Channel
      • 7.5.5.3 South Africa
      • 7.5.5.3.1 Key market trends, growth factors and opportunities
      • 7.5.5.3.2 Market size and forecast, by Indication
      • 7.5.5.3.3 Market size and forecast, by Drug Class
      • 7.5.5.3.4 Market size and forecast, by Distribution Channel
      • 7.5.5.4 Rest of LAMEA
      • 7.5.5.4.1 Key market trends, growth factors and opportunities
      • 7.5.5.4.2 Market size and forecast, by Indication
      • 7.5.5.4.3 Market size and forecast, by Drug Class
      • 7.5.5.4.4 Market size and forecast, by Distribution Channel

CHAPTER 8: COMPANY LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Key developments

CHAPTER 9: COMPANY PROFILES

  • 9.1 apotex inc.
    • 9.1.1 Company overview
    • 9.1.2 Company snapshot
    • 9.1.3 Operating business segments
    • 9.1.4 Product portfolio
    • 9.1.5 Business performance
    • 9.1.6 Key strategic moves and developments
  • 9.2 Aurobindo Pharma Ltd
    • 9.2.1 Company overview
    • 9.2.2 Company snapshot
    • 9.2.3 Operating business segments
    • 9.2.4 Product portfolio
    • 9.2.5 Business performance
    • 9.2.6 Key strategic moves and developments
  • 9.3 Biogen Idec
    • 9.3.1 Company overview
    • 9.3.2 Company snapshot
    • 9.3.3 Operating business segments
    • 9.3.4 Product portfolio
    • 9.3.5 Business performance
    • 9.3.6 Key strategic moves and developments
  • 9.4 Eisai
    • 9.4.1 Company overview
    • 9.4.2 Company snapshot
    • 9.4.3 Operating business segments
    • 9.4.4 Product portfolio
    • 9.4.5 Business performance
    • 9.4.6 Key strategic moves and developments
  • 9.5 Eli Lilly and Company
    • 9.5.1 Company overview
    • 9.5.2 Company snapshot
    • 9.5.3 Operating business segments
    • 9.5.4 Product portfolio
    • 9.5.5 Business performance
    • 9.5.6 Key strategic moves and developments
  • 9.6 Johnson & Johnson
    • 9.6.1 Company overview
    • 9.6.2 Company snapshot
    • 9.6.3 Operating business segments
    • 9.6.4 Product portfolio
    • 9.6.5 Business performance
    • 9.6.6 Key strategic moves and developments
  • 9.7 Abbvie Inc
    • 9.7.1 Company overview
    • 9.7.2 Company snapshot
    • 9.7.3 Operating business segments
    • 9.7.4 Product portfolio
    • 9.7.5 Business performance
    • 9.7.6 Key strategic moves and developments
  • 9.8 , F. Hoffmann-La Roche AG
    • 9.8.1 Company overview
    • 9.8.2 Company snapshot
    • 9.8.3 Operating business segments
    • 9.8.4 Product portfolio
    • 9.8.5 Business performance
    • 9.8.6 Key strategic moves and developments
  • 9.9 Teva Pharmaceutical Industries
    • 9.9.1 Company overview
    • 9.9.2 Company snapshot
    • 9.9.3 Operating business segments
    • 9.9.4 Product portfolio
    • 9.9.5 Business performance
    • 9.9.6 Key strategic moves and developments
  • 9.10 Novartis AG
    • 9.10.1 Company overview
    • 9.10.2 Company snapshot
    • 9.10.3 Operating business segments
    • 9.10.4 Product portfolio
    • 9.10.5 Business performance
    • 9.10.6 Key strategic moves and developments
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제